Table 4.
BMI-based subgroup analysis of biochemical and BMD characteristics in the olanzapine-treated group (n = 101).
| Normal weight (N = 50) | Overweight (N = 33) | Obesity (N = 18) | p ∗ | Multicomparison | |
|---|---|---|---|---|---|
| TG (mmol/L) | 1.55 ± 1.06 | 2.18 ± 1.82 | 2.66 ± 2.07 | 0.030 | No < Ob |
| CHOL (mmol/L) | 4.34 ± 0.82 | 4.43 ± 0.99 | 4.79 ± 0.68 | 0.241 | — |
| HDL (mmol/L) | 1.86 ± 1.05 | 1.68 ± 1.06 | 2.33 ± 1.24 | 0.162 | — |
| LDL (mmol/L) | 1.93 ± 0.72 | 2.01 ± 0.93 | 1.87 ± 0.90 | 0.851 | — |
| FBG (mmol/L) | 4.90 ± 0.81 | 5.25 ± 0.83 | 6.47 ± 2.94 | 0.001 | No, Ov < Ob |
| Insulin (μU/mL) | 17.89 ± 10.56 | 28.75 ± 20.91 | 22.41 ± 18.76 | 0.041 | No < Ob |
| BMD, radius+ulna (g/cm2) | |||||
| 1/3 | 0.67 ± 0.08 | 0.69 ± 0.07 | 0.68 ± 0.05 | 0.718 | — |
| MID | 0.55 ± 0.08 | 0.57 ± 0.07 | 0.67 ± 0.06 | 0.518 | — |
| UD | 0.43 ± 0.14 | 0.39 ± 0.10 | 0.43 ± 0.04 | 0.373 | — |
| TOTAL | 0.55 ± 0.07 | 0.56 ± 0.06 | 0.56 ± 0.07 | 0.583 | — |
| BMD, lumbar (g/cm2) | |||||
| L1 | 0.84 ± 0.09 | 0.88 ± 0.08 | 0.94 ± 0.07 | <0.001 | No, Ov < Ob |
| L2 | 0.89 ± 0.12 | 0.95 ± 0.11 | 1.01 ± 0.06 | 0.001 | No, Ov < Ob |
| L3 | 0.91 ± 0.11 | 0.96 ± 0.11 | 1.01 ± 0.09 | 0.009 | No < Ob |
| L4 | 1.14 ± 1.62 | 1.34 ± 1.12 | 1.03 ± 0.09 | 0.818 | — |
| L1-4 | 1.14 ± 0.78 | 1.36 ± 1.12 | 0.99 ± 0.08 | 0.808 | — |
| BMD, left hip (g/cm2) | |||||
| NECK | 0.74 ± 0.09 | 0.79 ± 0.12 | 0.85 ± 0.08 | 0.004 | No, Ov < Ob |
| TROCH | 0.62 ± 0.09 | 0.65 ± 0.11 | 0.72 ± 0.05 | 0.003 | No, Ov < Ob |
| WARD | 0.71 ± 0.11 | 0.75 ± 0.15 | 0.82 ± 0.08 | 0.019 | No < Ob |
| T-HIP | 0.83 ± 0.13 | 0.91 ± 0.11 | 0.98 ± 0.08 | <0.001 | No < Ov < Ob |
∗Comparison of biochemical and BMD characteristics among the normal weight, overweight, and obesity subgroups.